A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Trial Profile

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Docetaxel (Primary) ; Enzalutamide (Primary) ; Nivolumab (Primary) ; Rucaparib (Primary) ; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 9KD
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 05 Jun 2018 Trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to a Clovis Oncology media release, data will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 15 Feb 2018 Planned End Date changed from 30 Oct 2020 to 18 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top